Fiasp®
-
FDA approves Novo Nordisk’s Fiasp®
Oct 1, 2017News Hour: Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA’s decision comes... -
Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term
Sep 15, 2017News Hour: Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar and post-meal sugar control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings. The findings... -
Fiasp® by Novo Nordisk approved in Europe
Jan 11, 2017News Hour: Novo Nordisk announced that the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states. Fiasp® is the brand name for...
